I'm not sure how that's even relevant since any life saved counts( and this isn't a valid argument against releasing a new drug). Anyway yes, depending on the country of course but e.g. metastatic melanoma which was a death sentence has much better survival rates nowadays. You can also look up the small cell carcinoma 5 year survival rate with nivolumab for example. A similar thing is happening with more specialized drugs applied in specific stages of other cancer types in which case yes, the point that it's a small fraction of cancers holds true, but again, how is that an argument?